Market Cap
$132.9M
CRBU
Caribou Biosciences, Inc.
$1.23 ▲ +0.82%
Prev close $1.22Market cap$132.9M
ConsensusStrong Buy
12-mo target$11.86 (+864.0%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (4 insiders)26 New Institutional Positions6 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on CRBU right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Strong Buy (92%)
Inst. Holders
50 funds
Inst. Value
$62.0M
Inst. Activity
26 buys / 6 sells
Insider Activity
$0.00 buy / $47.5K sell
Insider Net $
-$47.5K
SEC Reports
8
Press Releases
2
Price chart 30d -23.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 17, 2026 short_volume
Short Volume: CRBU — 65.6% short (0.5M / 0.7M)
Short: 468,188 | Exempt: 600 | TRF Vol: 713,336 | Short Ratio: 65.6% | Off-exchange volume (dark poo
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
7,815,843 shares ($13.8M)
Jun 30, 2026 Inst.
Jun 11, 2026 SEC MACKENZIE FINANCIAL CORP — DOUBLED
3,650,796 shares ($6.4M)
Caribou Biosciences announced long-term follow-up data from its ANTLER phase 1 (vispa-cel, anti-CD19) and CaMMouflage ph
8-K — Impact 6/10
Caribou Biosciences reported longer follow-up data from the CaMMouflage Phase 1 trial of CB-011, an off-the-shelf BCMA-t
Impact 7/10
Caribou Biosciences filed a DEFA14A urging stockholders to vote ahead of the June 17, 2026 annual meeting. The board rec
DEFA14A — Impact 2/10
Caribou Biosciences is holding its 2026 annual meeting where shareholders will vote on electing three Class II directors
DEFA14A — Impact 3/10
Caribou Biosciences reported fourth quarter and full-year 2025 financial results, highlighting clinical progress in its
Impact 6/10
Analyst ratings buy % -1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
92% rate it Buy or better · 13 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 14, 2026 | B of A Securities | MAINTAIN | Buy | 54% |
| May 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Apr 7, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Aug 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Jul 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Jun 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 5 | 9 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 5 | 9 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 5 | 9 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% |
Price targets
Where 7 covering analysts think CRBU trades over the next 12 months.
$11.86 +864.0% upside Strong Buy
Current$1.23 Low$4.00 Median$10.00 High$32.00 7 analysts
$4.00$32.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
8 SEC filing reports analyzed · 1 bullish, 0 bearish, 1 mixed, 6 neutral · avg impact 3.9/10.Plus 2 press releases.
BULLISH8-K6/10
Caribou Biosciences announced long-term follow-up data from its ANTLER phase 1 (vispa-cel, anti-CD19
Jun 11, 2026
NEUTRALDEFA14A2/10
Caribou Biosciences filed a DEFA14A urging stockholders to vote ahead of the June 17, 2026 annual me
Jun 5, 2026
NEUTRALDEFA14A3/10
Caribou Biosciences is holding its 2026 annual meeting where shareholders will vote on electing thre
Apr 24, 2026
MIXED8-K5/10
Caribou Biosciences reported its 2025 financial results, showing a slight improvement in net loss de
Mar 5, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 17, 2026
short_volume
Short Volume: CRBU — 65.6% short (0.5M / 0.7M)
Short: 468,188 | Exempt: 600 | TRF Vol: 713,336 | Short Ratio: 65.6% | Off-exchange volume (dark pool + OTC)
Sep 15, 2026
short_volume
Short Volume: CRBU — 74.6% short (0.7M / 0.9M)
Short: 663,232 | Exempt: 77 | TRF Vol: 889,383 | Short Ratio: 74.6% | Off-exchange volume (dark pool + OTC)
Sep 14, 2026
short_volume
Short Volume: CRBU — 64.4% short (0.6M / 0.9M)
Short: 574,115 | Exempt: 10 | TRF Vol: 891,176 | Short Ratio: 64.4% | Off-exchange volume (dark pool + OTC)
Sep 11, 2026
short_volume
Short Volume: CRBU — 59.0% short (0.7M / 1.3M)
Short: 749,831 | Exempt: 4,871 | TRF Vol: 1,271,045 | Short Ratio: 59.0% | Off-exchange volume (dark pool + OTC)
Sep 10, 2026
short_volume
Short Volume: CRBU — 60.6% short (0.4M / 0.6M)
Short: 373,770 | Exempt: 1,993 | TRF Vol: 616,673 | Short Ratio: 60.6% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.30 | $-0.33–$-0.27 | — | +5.5% | 2↑ 0↓ | $0.0B | 4 |
| Next Q | $-0.36 | $-0.47–$-0.28 | — | -0.7% | 1↑ 1↓ | $0.0B | 4 |
| Current FY | $-1.18 | $-1.31–$-1.06 | — | +5.7% | 2↑ 0↓ | $0.0B | 4 |
| Next FY | $-1.26 | $-1.42–$-1.14 | -7.5% | +9.8% | 2↑ 0↓ | $0.0B | 3 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.302 | — |
| 7d ago | $-0.320 | +0.018 |
| 30d ago | $-0.320 | +0.018 |
| 60d ago | $-0.320 | +0.018 |
| 90d ago | $-0.320 | +0.018 |
Institutional ownership
Which big funds own CRBU (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $62.0M total value (35,218,755 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, MACKENZIE. Net buying activity: 26 institutions added/increased vs 6 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 7,815,843 | $13.8M | 22.2% | DOUBLED +264.7% |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,208,568 | $7.4M | 11.9% | — |
| MACKENZIE FINANCIAL CORP | 3,650,796 | $6.4M | 10.4% | DOUBLED +287.2% |
| RENAISSANCE TECHNOLOGIES LLC | 2,773,545 | $4.9M | 7.9% | ADD +58.0% |
| GEODE CAPITAL MANAGEMENT, LLC | 2,374,894 | $4.2M | 6.7% | DOUBLED +133.3% |
| STATE STREET CORP | 1,632,914 | $2.9M | 4.6% | DOUBLED +285.8% |
| BANK OF AMERICA CORP /DE/ | 1,410,958 | $2.5M | 4.0% | ADD +30.6% |
| TWO SIGMA INVESTMENTS, LP | 1,046,279 | $1.8M | 3.0% | — |
| DIMENSIONAL FUND ADVISORS LP | 975,327 | $1.7M | 2.8% | ADD +44.9% |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 775,809 | $1.4M | 2.2% | ADD +38.6% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | DOUBLED | 2,143,085 | 7,815,843 | +264.7% | $13.8M |
| MACKENZIE FINANCIAL CORP | DOUBLED | 942,786 | 3,650,796 | +287.2% | $6.4M |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 1,017,959 | 2,374,894 | +133.3% | $4.2M |
| STATE STREET CORP | DOUBLED | 423,263 | 1,632,914 | +285.8% | $2.9M |
| DIMENSIONAL FUND ADVISORS LP | ADD | 673,200 | 975,327 | +44.9% | $1.7M |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 559,642 | 775,809 | +38.6% | $1.4M |
| NORTHERN TRUST CORP | DOUBLED | 217,735 | 712,965 | +227.4% | $1.3M |
| Qube Research & Technologies Ltd | DOUBLED | 176,697 | 545,755 | +208.9% | $960.5K |
| UBS Group AG | ADD | 259,169 | 517,371 | +99.6% | $910.6K |
| MARSHALL WACE, LLP | TRIM | 1,205,668 | 375,686 | -68.8% | $661.2K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
13 insiders, 24 transactions. Net -$47.5K — $0.00 bought, $47.5K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 25, 2026 | Kelly Timothy P | Chief Technology Officer | SELL | 6,228 | $1.93 | $12.0K |
| Feb 24, 2026 | Kelly Timothy P | Chief Technology Officer | SELL | 3,147 | $1.96 | $6.2K |
| Feb 24, 2026 | Khan Ruhi Ahmad | Chief Business Officer | SELL | 6,938 | $1.96 | $13.6K |
| Feb 24, 2026 | MCCLUNG BARBARA G | Chief Legal Officer | SELL | 6,938 | $1.96 | $13.6K |
| Feb 24, 2026 | Albertson Tina M. | Chief Medical Officer | SELL | 1,066 | $1.96 | $2.1K |
| Feb 20, 2026 | MCCLUNG BARBARA G | Chief Legal Officer | AWARD | 202,500 | — | — |
| Feb 20, 2026 | Khan Ruhi Ahmad | Chief Business Officer | AWARD | 202,500 | — | — |
| Feb 20, 2026 | Kelly Timothy P | Chief Technology Officer | AWARD | 45,000 | — | — |
| Feb 20, 2026 | Sacks Natalie | Director | AWARD | 45,000 | — | — |
| Feb 20, 2026 | GUGGENHIME ANDREW | Director | AWARD | 45,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CRBU.
Shares short
12,978,605
Settlement Sep 15, 2026
Change vs prior
+3.8%
Semi-monthly cycle
Days to cover
9.5
At avg daily volume
Of shares outstanding
≈12.1%
Estimate — not % of float
All CRBU filing & press-release reports (10)
- 8-K reportJun 11, 2026
- PRESS-RELEASE reportJun 11, 2026
- DEFA14A reportJun 5, 2026
- DEFA14A reportApr 24, 2026
- 8-K reportMar 5, 2026
- PRESS-RELEASE reportMar 5, 2026
- INST-CLUSTER reportFeb 28, 2026
- CLUSTER reportFeb 27, 2026
- CLUSTER, CLUSTER reportFeb 25, 2026
- CLUSTER reportFeb 25, 2026